2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street
Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months.
Source: fool.com
Page 4 - Recursion Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Recursion Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Recursion Pharmaceutical Today - Breaking & Trending Today
2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street
Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months.
Source: fool.com
Contrasting Harpoon Therapeutics (NASDAQ:HARP) & Recursion Pharmaceuticals (NASDAQ:RXRX)
Harpoon Therapeutics (NASDAQ:HARP – Free Report) and Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership. Volatility and Risk Harpoon Therapeutics has a beta of […]
Source: tickerreport.com
Research Analysts Offer Predictions for Recursion Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) – Research analysts at KeyCorp issued their Q1 2024 earnings per share estimates for Recursion Pharmaceuticals in a research report issued to clients and investors on Monday, May 8th. KeyCorp analyst S. Schoenhaus expects that the company will earn ($0.33) per share for the quarter. The consensus estimate […]
Source: theenterpriseleader.com
Equities Analysts Set Expectations for Recursion Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) – Equities researchers at KeyCorp issued their Q1 2024 earnings per share (EPS) estimates for shares of Recursion Pharmaceuticals in a report released on Monday, May 8th. KeyCorp analyst S. Schoenhaus expects that the company will earn ($0.33) per share for the quarter. The consensus estimate for Recursion […]
Source: tickerreport.com